Article
Oncology
Mirat Shah, Christy L. Osgood, Anup K. Amatya, Mallorie H. Fiero, William F. Pierce, Abhilasha Nair, Jonathan Herz, Kim J. Robertson, Bronwyn D. Mixter, Shenghui Tang, Richard Pazdur, Julia A. Beaver, Laleh Amiri-Kordestani
Summary: The FDA has approved pembrolizumab in combination with chemotherapy for treating high-risk, early-stage triple-negative breast cancer. The addition of pembrolizumab significantly improves pathological complete response rate and event-free survival. Pembrolizumab demonstrates benefits regardless of tumor PD-L1 status.
CLINICAL CANCER RESEARCH
(2022)
Article
Nanoscience & Nanotechnology
Lin Li, Jian Fu, Xingyue Wang, Qiaoqi Chen, Wei Zhang, Yang Cao, Haitao Ran
Summary: The nanoplatelets derived from platelet membranes served as contrast agents for multimodal imaging and effectively enhanced the therapeutic performance in treating breast cancer.
ACS APPLIED MATERIALS & INTERFACES
(2021)
Review
Pharmacology & Pharmacy
Fuxu Yang, Mingyue Wang, Xingang Guan
Summary: Exosomes, as a new intercellular communication mode, show great potential in drug delivery, especially in cancer treatment. Synthetic exosome-mimics have also become an important drug delivery platform.
FRONTIERS IN PHARMACOLOGY
(2022)
Review
Chemistry, Multidisciplinary
B. H. Jaswanth Gowda, Mohammed Gulzar Ahmed, Mohammad Ali Abdullah Almoyad, Shadma Wahab, Waleed H. Almalki, Prashant Kesharwani
Summary: Nanosponges, with their unique sponge-like structure, offer a promising solution for drug delivery in cancer therapy. By utilizing their interconnected voids and mesh-like network, nanosponges enable efficient drug loading and controlled release, overcoming the limitations of conventional methods. They show potential in both cancer treatment and diagnosis, and are considered versatile carrier systems.
ADVANCED FUNCTIONAL MATERIALS
(2023)
Review
Chemistry, Multidisciplinary
Vijay Sagar Madamsetty, Shima Tavakol, Saeid Moghassemi, Arezoo Dadashzadeh, John D. Schneible, Iman Fatemi, Abdolsamad Shirvani, Ali Zarrabi, Fereshteh Azedi, Ali Dehshahri, Abbas Aghaei Afshar, Kian Aghaabbasi, Abbas Pardakhty, Reza Mohammadinejad, Prashant Kesharwani
Summary: Breast cancer is a highly deadly neoplastic disease with limited efficacy in existing treatment methods, prompting a search for new remedies. Nanotechnology has shown promise in the field, particularly with chitosan as a potential carrier for anticancer drugs. Further research is ongoing to explore the therapeutic and diagnostic applications of chitosan in breast cancer treatment.
JOURNAL OF CONTROLLED RELEASE
(2022)
Review
Oncology
Gavin P. Dowling, Stephen Keelan, Sinead Toomey, Gordon R. Daly, Bryan T. Hennessy, Arnold D. K. Hill
Summary: This article reviews the evolving treatment strategies in the neoadjuvant setting of HER2-positive breast cancer, discussing current challenges and future perspectives. The current standard of care combines chemotherapy with dual anti-HER2 therapy for high-risk HER2-positive breast cancer, aiming for a synergistic anti-tumor effect. De-escalation strategies are being investigated to safely reduce chemotherapy while optimizing HER2-targeted therapies, and promising novel therapies are being explored to improve outcomes in HER2-positive breast cancer.
FRONTIERS IN ONCOLOGY
(2023)
Article
Oncology
Rainjade Chung, James McKiernan, Nicholas Arpaia, Aurelien Marabelle, Mathieu Rouanne
Summary: BCG is a live attenuated strain of Mycobacterium bovis, initially developed as a vaccine for tuberculosis. It is the only bacterial therapy approved by the US FDA for clinical use in cancer treatment. BCG is used in patients with high-risk non-muscle invasive bladder cancer, delivered directly into the bladder after tumor resection. Modulating mucosal immunity by exposing the urothelium to BCG has been the main therapeutic approach for this type of cancer.
EUROPEAN JOURNAL OF CANCER
(2023)
Article
Pharmacology & Pharmacy
Manali Jadhav, Rajendra Prasad, Mayuri Gandhi, Rohit Srivastava
Summary: The use of biodegradable nanoparticles as drug carriers has gained attention worldwide. In this study, erythrocyte-derived nanovesicles were extracted from mouse blood and loaded with doxorubicin for targeted cancer chemotherapy. The surface markers on these nanovesicles were identified using mass spectrometry, which could potentially be used for targeting cancer cells. The uniform particle size distribution was confirmed through dynamic light scattering measurements. Cell viability and confocal microscopy studies showed effective cancer cell killing by these drug-loaded nanocarriers.
JOURNAL OF DRUG DELIVERY SCIENCE AND TECHNOLOGY
(2022)
Article
Oncology
Yujin Lee, Peter Graham, Yong Li
Summary: Breast cancer lacks effective management approaches for metastasis and therapy-resistant disease. Extracellular vesicles (EVs) play an important role in intercellular communication and are associated with pathological conditions. Cancer cells secrete EVs and communicate with neighboring cells in the tumor microenvironment, which contributes to BC metastasis, immune escape, and chemo-resistance. EVs have emerged as potential therapeutic targets and carriers for BC treatment, stimulating angiogenesis, inhibiting the immune response, and promoting cancer metastasis.
Article
Biotechnology & Applied Microbiology
Xingfeng He, Yan Jiang, Long Zhang, Yaqi Li, Xiang Hu, Guoqiang Hua, Sanjun Cai, Shaobo Mo, Junjie Peng
Summary: In this study, a biobank of 42 organoids derived from primary and metastatic lesions of metastatic colorectal cancer (mCRC) patients was successfully established. The organoids maintained the genetic and phenotypic heterogeneity of their parental tumors, and drug sensitivity assays revealed their potential value for predicting chemotherapy response and clinical outcomes. This study demonstrates that patient-derived organoids can guide personalized treatment decisions for patients with end-stage CRC.
FRONTIERS IN BIOENGINEERING AND BIOTECHNOLOGY
(2023)
Article
Oncology
Jikun Feng, Jiarong Yi, Xiazi Zouxu, Jianxia Li, Zhenchong Xiong, Xinjian Huang, Wenjing Zhong, Weiling Huang, Feng Ye, Xi Wang
Summary: This study aimed to explore the relationship between peripheral blood lymphocyte subset distribution and the efficacy of neoadjuvant therapy in breast cancer. The results showed that baseline levels of CD3+ T cells, CD8+ T cells, and NK cells were independent predictors of pathological complete response (pCR). Among them, CD8+ T cells had the highest predictive ability.
Review
Chemistry, Multidisciplinary
Shuxin Xu, Lisheng Wang, Zhen Liu
Summary: Molecularly imprinted polymers (MIPs) are tailor-made affinity materials with unique binding cavities, which have been engineered for cancer therapy. Using nanoMIPs as alternatives to current nanomaterials offers potential solutions to existing challenges in biological ligand-based nanomedicines.
ANGEWANDTE CHEMIE-INTERNATIONAL EDITION
(2021)
Review
Oncology
Federica Miglietta, Maria Vittoria Dieci, Gaia Griguolo, Valentina Guarneri
Summary: Neoadjuvant therapy provides significant clinical benefits for breast cancer patients and serves as a strategic tool in research. Pathologic complete response is a key prognostic indicator, and the impact of different treatment strategies on pathologic complete response rate and patient prognosis is a major focus of investigation.
CANCER TREATMENT REVIEWS
(2021)
Article
Oncology
Srivarshini Cherukupalli Mohan, Sarah Walcott-Sapp, Minna K. Lee, Marissa K. Srour, Sungjin Kim, Farin F. Amersi, Armando E. Giuliano, Alice P. Chung
Summary: This study examined the impact of biomarker changes in residual disease patients after neoadjuvant systemic therapy on disease-free survival and overall survival. The results showed that biomarker status change was common and affected survival in subgroups of HR+ or TN disease. Retesting biomarkers after NAT has prognostic implications.
ANNALS OF SURGICAL ONCOLOGY
(2021)
Article
Oncology
Jose Pablo Leone, Michael J. Hassett, Julieta Leone, Sara M. Tolaney, Carlos T. Vallejo, Bernardo A. Leone, Eric P. Winer, Nancy U. Lin
Summary: This study compares the proportions of pathologic complete response (pCR) between male breast cancer (MaBC) and female breast cancer (FBC) in neoadjuvant chemotherapy (NAC), and finds that FBC has higher pCR rates. Furthermore, pCR is associated with survival rates in both MaBC and FBC.